ReviewFrontiers in immunology2026
OTULIN: a master regulator of linear ubiquitin homeostasis in immune signaling, inflammation, and disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OTU deubiquitinase with linear linkage specificity (OTULIN) is the only deubiquitinase known to exhibit strict specificity for Met1-linked linear ubiquitin chains, serving as a critical regulator that restrains linear ubiquitin chain assembly complex and maintains inflammatory homeostasis and tissue integrity. Advances over recent years have reshaped our understanding of OTULIN from a negative regulator confined to the canonical nuclear factor kappa-light-chain-enhancer of activated B cells pathway to a central editor governing linear ubiquitin network homeostasis. Its functional repertoire spans receptor-proximal inflammatory signaling, cell death fate determination, inflammasome activation, autophagy, and cellular stress adaptation. Emerging evidence from human genetics and animal models has further broadened the OTULIN-associated disease spectrum, revealing that pathogenesis arises from imbalanced linear ubiquitin networks coupled with cell type and tissue context dependent inflammatory dysregulation. Here, we provide a comprehensive overview of OTULIN's structural features, regulatory mechanisms, biological functions, roles in pathogenesis, and potential therapeutic intervention strategies, aiming to inform future mechanistic studies and facilitate translational advances in targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.